On the morning of April 14, Zhao Lei, a professional expert in the field of sterile technology of Trane Biotechnology, shared the "Exploration and Practice of Industrialization Equipment for Immune Cell Drugs". Zhao Lei pointed out that immune cell drugs are a new type of biological products with the advantages of significant efficacy and high safety, and are an important development direction in the field of biomedicine in the future. However, cost reduction and efficiency improvement have become a major challenge in the cell therapy industry, which needs to be solved through technological innovation and equipment upgrades. Among immune cell drugs, CAR-T cells account for the largest proportion at all stages, and TCR-T, NK, TIL, etc. also show a growth trend. When looking at the selection of immune cell industrialization routes from a regulatory perspective, multiple aspects such as production processes, equipment, and environment need to be taken into consideration. Only production processes and equipment that meet GMP requirements can ensure product quality and safety. For this reason, the exploration and practice of domestically produced equipment that meets GMP requirements is particularly important.

Through continuous practice and improvement, Trane Biotech has successfully developed domestically produced equipment that meets GMP requirements, such as cell processing isolators, cell preparation isolators, and culture honeycomb systems, providing strong support for the industrialization of immune cell drugs.